Latest Federal Register Notices
Drug Safety/Anesthetic and Analgesic Meeting Address Change
Federal Register Notice: FDA amends a 1/11 notice of a Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee joint meeting. 03/08/2017
Flonase Not Withdrawn Due to Safety/Effectiveness
Federal Register Notice: FDA determines that GlaxoSmithKline’s allergy drug Flonase (fluticasone propionate) nasal spray, 0.05 mg, was not withdrawn from sale for safety or effectiveness reasons. 03/06/2017
Public Meeting on Autism Drug Development
Federal Register Notice: FDA announces a 5/4 public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. 03/06/2017
Biogen Awarded Priority Review Voucher
Federal Register Notice: FDA awards Biogen a priority review voucher for gaining approval of rare disease drug Spinraza (nusinersen), indicated for treating spinal muscular atrophy in pediatric and adult patients. 03/06/2017